Sino Biopharm Reports Strong 2025 Results with 26.2% Growth in Innovative Drug Sales
核心洞察
Sino Biopharmaceutical achieved RMB 15.22 billion in innovative product sales for 2025, representing a 26.2% year-on-year increase and accounting for 47.8% of total revenue.
The company secured NMPA approval for four innovative products in 2025, including Saitanxin (搜索) (Culmerciclib Capsules) and Hernexeos (搜索) (Zongertinib Tablets) for oncology applications.
The company's robust pipeline includes 69 innovative drug candidates across four therapeutic areas, with nearly 20 national category 1 innovative drugs expected to receive marketing approval by 2028.
Sino Biopharmaceutical Limited reported robust financial performance for 2025, with total revenue increasing 10.3% to RMB 31.83 billion and innovative product sales surging 26.2% to RMB 15.22 billion. The Chinese pharmaceutical giant's innovative products now represent 47.8% of total revenue, demonstrating the company's successful transition toward innovation-driven growth.
The company achieved significant regulatory milestones in 2025, securing NMPA approval for four innovative products: Saitanxin (搜索) (Culmerciclib Capsules), Hernexeos (搜索) (Zongertinib Tablets), Putanning (搜索) (Meloxicam Injection II), and Anqixin (Recombinant Human Coagulation Factor VIIa N01 for Injection). These approvals contributed to accelerated sales growth across the company's innovative portfolio.
Oncology Portfolio Drives Revenue Growth
Oncology drug sales increased 22.8% year-on-year to RMB 13.18 billion, accounting for 41.4% of total revenue. The company's flagship product, Focus V (搜索) (Anlotinib Hydrochloride Capsules), a multi-target tyrosine kinase (搜索) inhibitor, has been approved for 10 indications with several new indications in Phase III trials, including first-line non-squamous non-small cell lung cancer and first-line pancreatic cancer.
From 2023 to 2025, Sino Biopharm obtained marketing approval for seven national category 1 innovative oncology drugs and four oncology biosimilars. The portfolio includes Yilishu (Efbemalenograstim alfa Injection), Andewei (Benmelstobart Injection), Anboni (Unecritinib Fumarate Capsules), Anluoqing (Envonalkib Citrate Capsules), and Anfangning (Garsorasib Tablets), alongside biosimilars Anbeisi (Bevacizumab Injection), Delituo (Rituximab Injection), Saituo (Trastuzumab for Injection), and Paletan (Pertuzumab Injection).
Comprehensive Pipeline Across Four Therapeutic Areas
As of December 31, 2025, Sino Biopharm maintained a robust pipeline of 69 innovative drug candidates across its four core therapeutic areas. The pipeline includes 39 innovative oncology drug candidates, 10 liver/cardiometabolic drug candidates, 14 respiratory/autoimmune drug candidates, and 6 surgery/analgesia drug candidates.
Currently, one innovative oncology drug candidate and two innovative surgery/analgesia drug candidates are in the marketing application stage. The company has 20 drug candidates in Phase III clinical trials, including 13 oncology candidates, one liver/cardiometabolic candidate, five respiratory/autoimmune candidates, and one surgery/analgesia candidate.
Pain Management and Respiratory Pipeline Advances
In surgery/analgesia, Zepolas/Debaian (Flurbiprofen Cataplasms) maintains market leadership in topical analgesia. The second-generation flurbiprofen patch is expected to receive marketing approval within one year, featuring enhanced transdermal absorption and improved adhesiveness. Putanning (搜索) (Meloxicam Injection II), China's first once-daily long-acting analgesic NSAIDs injection, received NMPA and FDA approval in May 2025 and was included in the National Reimbursement Drug List.
For respiratory diseases, TQC3721, a dual PDE3/4 (搜索) inhibitor, is undergoing Phase III clinical trials for moderate to severe chronic obstructive pulmonary disease (COPD). The company is developing multiple dosage forms, with a suspension for inhalation in Phase III trials and an inhaled dry powder formulation in Phase II trials.
Substantial R&D Investment and Patent Portfolio
Sino Biopharm invested RMB 6.32 billion in R&D during 2025, representing 19.8% of total revenue. The company has established multiple R&D centers in Shanghai, Nanjing, Beijing, and Guangzhou, building diversified technology platforms covering small molecules, protein degraders, siRNA, monoclonal/bispecific antibodies, antibody-drug conjugates (ADC), inhalation formulations, and transdermal patches.
The company filed 1,167 new patent applications and received 273 patent grants during 2025. As of year-end, Sino Biopharm had accumulated 5,724 valid patent applications and obtained 2,120 valid patent grants.
International Expansion Strategy
In February 2026, Sino Biopharm announced an exclusive worldwide licensing agreement with Sanofi for Rovadicitinib, with potential payments up to US$1.53 billion plus tiered royalties reaching double digits based on annual net sales. This partnership represents a significant milestone in the company's internationalization strategy and establishes out-licensing as an important revenue source.
The company projects nearly 20 national category 1 innovative drugs will receive marketing approval over the next three years (2026-2028), including multiple blockbuster products with first-in-class and best-in-class potential. By the end of 2028, Sino Biopharm expects to have approximately 40 innovative products launched, positioning these products as core drivers of business growth.